Live from the NIH registry
Studies recruiting near Salinas right now
Top 25 of 46 recruiting studies, sorted by proximity — each links to its official registry page
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
Phase 3
Interventional 3,960 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: NRG Oncology
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 2,400 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: SWOG Cancer Research Network
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
Phase 3
Interventional 1,210 participants sought
Dominican Santa Cruz Hospital — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast Cancer, Early Breast Cancer
Phase 3
Interventional 5,500 participants sought
Research Site — Monterey, California (15.8 mi)
· Sponsor: AstraZeneca
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma
Phase 2
Interventional 152 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
N/A
Observational 130 participants sought
Pacific Cancer Care — Monterey, California (15.8 mi)
· Sponsor: N-Power Medicine
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma
Phase 3
Interventional 1,450 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)
Phase 2
Interventional 195 participants sought
Central Coast Nephrology — Salinas, California (1.5 mi)
· Sponsor: Regeneron Pharmaceuticals
Galleri® in the Medicare Population.
Cancer
N/A
Interventional 50,000 participants sought
Sutter Valley Hospitals PAMF Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: GRAIL, Inc.
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
N/A
Observational 8,000 participants sought
Salinas Surgery Center — Salinas, California (1.5 mi)
· Sponsor: Stryker Instruments
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
Phase 3
Interventional 1,670 participants sought
Dominican Santa Cruz Hospital — Santa Cruz, California (29.6 mi)
· Sponsor: NRG Oncology
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Phase 3
Interventional 4,220 participants sought
Pacific Cancer Care - Oncology — Monterey, California (15.8 mi)
· Sponsor: Stemline Therapeutics, Inc.
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Multiple Myeloma
Phase 1
Interventional 134 participants sought
Pacific Cancer Care — Monterey, California (15.8 mi)
· Sponsor: Oncotherapeutics
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Phase 3
Interventional 1,295 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Phase 3
Interventional 336 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: National Cancer Institute (NCI)
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Phase 2, Phase 3
Interventional 189 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 2
Interventional 66 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: SWOG Cancer Research Network
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma
Phase 3
Interventional 382 participants sought
Palo Alto Medical Foundation-Santa Cruz — Santa Cruz, California (29.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Salinas Valley Memorial — Salinas, California (1.5 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical Settings
Anxiety, Mood Disorders
N/A
Interventional 156 participants sought
Ohana Center for Child and Adolescent Behavioral Health — Monterey, California (15.8 mi)
· Sponsor: Stanford University
Toddlers' Responses to Strangers
Social Behavior
N/A
Observational 100 participants sought
Social Science 2 Building — Santa Cruz, California (29.6 mi)
· Sponsor: University of California Santa Cruz
Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)
Middle Schools, School Exclusion
N/A
Interventional 5,076 participants sought
Soquel Union Elementary School District — Capitola, California (26.6 mi)
· Sponsor: University of Oregon